- Austria (Website)
- Czech Republic (Website)
- Denmark (Website)
- Finland (Website)
- France (Website)
- Germany (Website)
- Italy (Website)
- Ivory Coast
Third Annual Step-On-Sepsis™ 5K Event on May 7th Recognized by state of North Carolina as “Sepsis Awareness Day”02 May, 2016
bioMerieux and Sepsis Alliance co-sponsor the largest NC fundraiser designed to raise awareness on the importance of prevention through early detection of sepsis, the 10th Leading Cause of Death in the U.S.
Durham, NC- May 2, 2016 – bioMérieux, Inc., a subsidiary of bioMérieux, a world leader in the field of in vitro diagnostics, is partnering with Sepsis Alliance, the leading nonprofit patient advocacy organization in North America promoting sepsis awareness, to support the third annual “Step-On-Sepsis” 5K Run & Walk in Cary on Saturday, May 7th. This day has also been proclaimed “Sepsis Awareness Day” by the state of North Carolina. bioMérieux is the 2016 National Sepsis Awareness and Education Title Sponsor for the Sepsis Alliance and will support the National Sepsis Challenge™ public awareness campaign that includes a series of educational events, kicking off with Step on Sepsis.
The Step-On-Sepsis™ 5K Run and Walk begins at 7:00 a.m. with onsite registration and various pre-race events including a special presentation made by North Carolina State Health Director, Dr. Randall Williams. He will present a proclamation from the state of North Carolina declaring the day “Sepsis Awareness Day” in the state to further encourage families and physicians be vigilant to recognize sepsis as early as possible. Participants should arrive by 8 a.m. to complete registration in time for the 9 a.m. start of the race.
Step-On-Sepsis was created to honor the memory of a local Cary man, Jerry Minore, an otherwise healthy 55-year old man who died from sepsis. His neighbors, Helene and Jeff Zehnder, initiated the event in commemoration of Jerry and to raise awareness of sepsis. Local sepsis survivor, Carol Fowler Durham, a nurse educator at the University of North Carolina School of Nursing, is this year’s Honorary Event Chair. Carol nearly died from septic shock in 2010. Now she travels around the country and speaks to healthcare professionals and nursing students about patient safety, interweaving her personal experience with sepsis. Carol also serves as patient advisor in the implementation of UNC Medical Center’s sepsis reduction initiative, Code Sepsis.
Other local organizations that will attend in support of sepsis recognition include Cary Boy Scout Troop #213, Great Harvest Bread Company, Creative Visions, and Rusty Wagstaff, last year’s Honorary Event Chair of the Step On Sepsis Challenge and sepsis survivor.
To learn more details and register for the event, visit the Step On Sepsis website.
Sepsis is a life-threatening complication of a systemic bloodstream infection. One contributing factor to the increasing incidence of sepsis worldwide is the rise of antibiotic-resistant bacteria, which are very difficult—if not impossible—to treat with currently available antibiotics. Sepsis can rapidly progress to septic shock, which is highly fatal. With no current therapy available, it’s vital to detect sepsis as soon as possible to avert septic shock. The first 24 hours in the course of a sepsis patient’s management can be decisive for their very survival. bioMérieux, a pioneer in rapid diagnostics, offers technology that assists physicians in the detection and diagnosis of sepsis within the first 24 hours of onset. To learn how to protect yourself and loved ones from sepsis, visit www.sepsisknowfromday1.com.
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1,965 million with 90% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market (Code: BIM / Reuters: BIOX.PA / Bloomberg: BIM.FP – ISIN: FR0010096479).
Other information can be found at www.biomerieux-usa.com
Tel: +1 216-407-5354
Tel: + 1 330-338-6633
Download the Press Release: